Resistant Pseudomonas Aeruginosa Infections - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 60 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Resistant Pseudomonas Aeruginosa Infections - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Resistant Pseudomonas Aeruginosa Infections - Pipeline Review, H2 2014', provides an overview of the Resistant Pseudomonas Aeruginosa Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Resistant Pseudomonas Aeruginosa Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Resistant Pseudomonas Aeruginosa Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Resistant Pseudomonas Aeruginosa Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Resistant Pseudomonas Aeruginosa Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Resistant Pseudomonas Aeruginosa Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Resistant Pseudomonas Aeruginosa Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Resistant Pseudomonas Aeruginosa Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Resistant Pseudomonas Aeruginosa Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Resistant Pseudomonas Aeruginosa Infections Overview 7
Therapeutics Development 8
Pipeline Products for Resistant Pseudomonas Aeruginosa Infections - Overview 8
Pipeline Products for Resistant Pseudomonas Aeruginosa Infections - Comparative Analysis 9
Resistant Pseudomonas Aeruginosa Infections - Therapeutics under Development by Companies 10
Resistant Pseudomonas Aeruginosa Infections - Therapeutics under Investigation by Universities/Institutes 11
Resistant Pseudomonas Aeruginosa Infections - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Resistant Pseudomonas Aeruginosa Infections - Products under Development by Companies 14
Resistant Pseudomonas Aeruginosa Infections - Products under Investigation by Universities/Institutes 15
Resistant Pseudomonas Aeruginosa Infections - Companies Involved in Therapeutics Development 16
AstraZeneca PLC 16
Biolytics Pharma 17
FOB Synthesis, Inc. 18
LegoChem Biosciences, Inc 19
Melinta Therapeutics, Inc 20
Microbion Corporation 21
Phico Therapeutics Ltd. 22
Phylogica Limited 23
Shionogi & Co., Ltd. 24
Resistant Pseudomonas Aeruginosa Infections - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
Biologic for Pseudomonas Aeruginosa Infection - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Cephalosporin + Beta-Lactamase Inhibitor - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
CSA-13 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
FSI-1671 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
G-10 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
LCB-100200 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
PT-3.33 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
RXP-763 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
RXP-766 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
RXP-770 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
RXP-793 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
RXP-808 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
RXP-873 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
S-649266 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Small Molecule for Chronic Wound Infection - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Small Molecules for Multi-Drug Resistant Bacterial Infections - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Resistant Pseudomonas Aeruginosa Infections - Recent Pipeline Updates 55
Resistant Pseudomonas Aeruginosa Infections - Dormant Projects 58
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 60
Disclaimer 60

List of Tables
Number of Products under Development for Resistant Pseudomonas Aeruginosa Infections, H2 2014 8
Number of Products under Development for Resistant Pseudomonas Aeruginosa Infections - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Resistant Pseudomonas Aeruginosa Infections - Pipeline by AstraZeneca PLC, H2 2014 16
Resistant Pseudomonas Aeruginosa Infections - Pipeline by Biolytics Pharma, H2 2014 17
Resistant Pseudomonas Aeruginosa Infections - Pipeline by FOB Synthesis, Inc., H2 2014 18
Resistant Pseudomonas Aeruginosa Infections - Pipeline by LegoChem Biosciences, Inc, H2 2014 19
Resistant Pseudomonas Aeruginosa Infections - Pipeline by Melinta Therapeutics, Inc, H2 2014 20
Resistant Pseudomonas Aeruginosa Infections - Pipeline by Microbion Corporation, H2 2014 21
Resistant Pseudomonas Aeruginosa Infections - Pipeline by Phico Therapeutics Ltd., H2 2014 22
Resistant Pseudomonas Aeruginosa Infections - Pipeline by Phylogica Limited, H2 2014 23
Resistant Pseudomonas Aeruginosa Infections - Pipeline by Shionogi & Co., Ltd., H2 2014 24
Assessment by Monotherapy Products, H2 2014 25
Assessment by Combination Products, H2 2014 26
Number of Products by Stage and Target, H2 2014 28
Number of Products by Stage and Mechanism of Action, H2 2014 30
Number of Products by Stage and Route of Administration, H2 2014 32
Number of Products by Stage and Molecule Type, H2 2014 34
Resistant Pseudomonas Aeruginosa Infections Therapeutics - Recent Pipeline Updates, H2 2014 55
Resistant Pseudomonas Aeruginosa Infections - Dormant Projects, H2 2014 58